Roxatidine Acetate
| Evidence Level: L1 | Predicted Indications: 6 |
Table of Contents
- Roxatidine Acetate
- Roxatidine Acetate: From Unregistered H2-Receptor Antagonist to Active Peptic Ulcer Disease
Roxatidine Acetate: From Unregistered H2-Receptor Antagonist to Active Peptic Ulcer Disease
One-Sentence Summary
Roxatidine acetate is a histamine H2-receptor antagonist with no recorded original indication in the current regulatory dataset (drug is not marketed in India/Taiwan). The TxGNN model predicts it may be effective for Active Peptic Ulcer Disease, and this direction is strongly corroborated by 2 randomized controlled trials and 13 additional publications, largely because this is in fact the drug’s well-established historical use as an antisecretory agent rather than a novel mechanistic leap.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in dataset (no Taiwan/India license on file) |
| Predicted New Indication | Active Peptic Ulcer Disease |
| TxGNN Prediction Score | 99.58% |
| Evidence Level | L1 |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed DrugBank-sourced mechanism-of-action data is not currently available for this candidate. However, the accompanying literature evidence fills this gap: roxatidine acetate is rapidly converted by esterases to its active metabolite roxatidine, a potent H2-receptor antagonist that inhibits basal and histamine-stimulated gastric acid secretion in parietal cells. Unlike cimetidine, it does not exhibit anti-androgenic effects or interfere with hepatic (CYP-mediated) drug metabolism (PMID 1717223, 2906472). Preclinical work additionally demonstrates a cytoprotective action independent of pure acid suppression, involving endogenous prostaglandin pathways (PMID 2906796, 9379358).
This mechanism is the textbook, non-inferential basis for treating peptic ulcer disease — acid suppression combined with mucosal protection directly addresses the pathophysiology of gastric and duodenal ulcers. Notably, this is not a true “repurposing” scenario in the conventional sense: the predicted indication (active peptic ulcer disease) is the class-defining, historically established use of H2-receptor antagonists like roxatidine, dating to clinical development in the late 1980s–1990s. The TxGNN model has effectively rediscovered the drug’s original therapeutic niche rather than identifying a novel disease association.
Given that this drug currently has zero regulatory registrations in India/Taiwan and no recorded “original indication” in the local dataset, the practical value of this prediction lies in supporting a first-time market entry submission for peptic ulcer disease, using decades of existing global clinical evidence, rather than validating a genuinely new therapeutic direction.
Clinical Trial Evidence
Currently no related clinical trials registered (no entries found in clinical_trials or ictrp_trials).
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 1674231 | 1991 | RCT | Clinical Therapeutics | Two 12-month, double-blind, placebo-controlled multicenter maintenance studies (n=725); 75mg nightly roxatidine reduced duodenal and gastric ulcer relapse vs. placebo |
| 1352083 | 1992 | RCT | Am J Gastroenterol | 4-week double-blind RCT in active duodenal ulcer; roxatidine healing rate 33.9% vs. placebo 21.9% at week 2 (p=0.018), sustained advantage through week 4 |
| 8527619 | 1995 | RCT | Aliment Pharmacol Ther | Double-blind RCT comparing early-evening vs. bedtime roxatidine 150mg dosing in short-term duodenal ulcer treatment; comparable efficacy and tolerability between regimens |
| 1717223 | 1991 | Review | Drugs | Comprehensive PK/PD review: >95% oral absorption, potent basal/stimulated acid suppression, no anti-androgenic effects, no hepatic enzyme interference |
| 2906456 | 1988 | Review | Scand J Gastroenterol Suppl | 150mg identified as optimal dose for acid suppression; modified-release capsule sustains nocturnal acid control; confirmed ulcer-healing efficacy in trials |
| 2906472 | 1988 | Review (DDI focus) | Scand J Gastroenterol Suppl | Contrasts roxatidine’s minimal hepatic microsomal enzyme interaction with cimetidine/ranitidine, suggesting lower drug-interaction risk profile |
| 2184124 | 1990 | Review | Gastroenterol Clin North Am | Overview of PUD medical therapy; roxatidine and nizatidine noted as safe, effective new H2 blockers without added clinical advantage over existing agents |
| 8097411 | 1993 | Review | Bailliere’s Clin Gastroenterol | Mechanistic review of gastric acid regulation (ACh/gastrin/histamine pathways), providing pharmacological basis for H2RA antisecretory action |
| 2906796 | 1988 | Preclinical | Arch Int Pharmacodyn Ther | Demonstrates cytoprotective action against ethanol-induced gastric mucosal lesions, partly prostaglandin-mediated, distinct from acid suppression |
| 9379358 | 1997 | Preclinical | J Pharm Pharmacol | Rat stress-ulcer model: MX1 (roxatidine-bismuth-citrate complex) showed enhanced gastroprotection vs. equimolar roxatidine alone |
India Market Information
Roxatidine acetate is currently not marketed in India (0 registrations on file); no authorization records are available for review.
Safety Considerations
Please refer to the package insert for safety information. (Key warnings, contraindications, and DDI data are currently unavailable — flagged as a Blocking data gap, see Conclusion below.)
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The efficacy evidence for roxatidine acetate in active peptic ulcer disease is strong (L1 — multiple completed RCTs plus a substantial supporting literature base spanning three decades), and the mechanism is well-established rather than speculative. However, this drug is unregistered in India/Taiwan and safety labeling data (warnings, contraindications) is entirely missing (DG001, Blocking severity) — this must be resolved before any S1 safety evaluation or market submission can proceed. Lower-ranked predicted indications (gastrojejunal ulcer, peptic ulcer perforation, gastroduodenitis, duodenogastric reflux, duodenal obstruction) are all L5 (model-prediction only, no supporting evidence) and are recommended for Hold — several (e.g., perforation, structural obstruction) are mechanistically inappropriate for an antisecretory agent and should be deprioritized or excluded from further evaluation.
To proceed, the following is needed:
- Official product label / package insert (warnings, contraindications, DDI) — source: regulatory agency label database (Blocking, per DG001)
- Formal DrugBank MOA record to replace literature-derived mechanism summary (DG002)
- Confirmation of dosage form and route availability for the local market
- If pursuing India market entry: full CDSCO registration dossier referencing the existing global RCT evidence base for peptic ulcer disease
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.